Laparoscopic sleeve gastrectomy in morbidly obese patients with end-stage heart failure and left ventricular assist device

Medium-term results

Umer I. Chaudhry, Aliyah Kanji, Chittoor Sai Sudhakar, Robert S. Higgins, Bradley J. Needleman

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background Morbid obesity precludes patients with end-stage heart failure from becoming cardiac transplant candidates. This study evaluates the safety and efficacy of laparoscopic sleeve gastrectomy (LSG) as a means to transplant candidacy in such patients. Methods Morbidly obese patients with end-stage heart failure, who were ineligible for cardiac transplantation and underwent LSG between 2008 and 2013, were reviewed retrospectively. Demographic characteristics, perioperative details, percentage of excess weight loss (%EWL), and status of transplant candidacy were analyzed. Results Six patients (3 men) with end-stage heart failure and morbid obesity underwent LSG. Three patients (50%) had a left ventricular assist device (LVAD) in place at the time of surgery. Median age was 34 (31-66) years and mean preoperative body mass index (BMI) was 47.6±3.0 kg/m2. Median operative time was 90 (66-141) minutes, with a median length of stay of 7 (4-16) days. There were no perioperative deaths. One patient suffered a spontaneous flank hematoma. The same patient also had thrombosis of the LVAD pump at 3 weeks postoperatively, requiring an uneventful device exchange. At median follow-up of 22 (12-70) months, the mean %EWL was 51.4±10.3% with a decrease in BMI to 34.3±2.4 kg/m2 (P<.05). All patients had lost sufficient weight to become transplant eligible within 12 months of surgery. Two patients had undergone successful transplantation and another 2 were on the transplant list. Conclusion LSG appears to be a safe, technically feasible, and effective method for obtaining adequate weight loss in morbidly obese patients with end-stage heart failure and mechanical circulatory support, subsequently improving their access to cardiac transplantation. This is the largest case series to date of this high-risk group of patients undergoing LSG.

Original languageEnglish (US)
Pages (from-to)88-93
Number of pages6
JournalSurgery for Obesity and Related Diseases
Volume11
Issue number1
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Heart-Assist Devices
Gastrectomy
Heart Failure
Transplants
Morbid Obesity
Heart Transplantation
Weight Loss
Body Mass Index
Operative Time
Hematoma
Length of Stay
Thrombosis
Transplantation
Demography

All Science Journal Classification (ASJC) codes

  • Surgery
  • Medicine(all)

Cite this

Laparoscopic sleeve gastrectomy in morbidly obese patients with end-stage heart failure and left ventricular assist device : Medium-term results. / Chaudhry, Umer I.; Kanji, Aliyah; Sai Sudhakar, Chittoor; Higgins, Robert S.; Needleman, Bradley J.

In: Surgery for Obesity and Related Diseases, Vol. 11, No. 1, 01.01.2015, p. 88-93.

Research output: Contribution to journalArticle

@article{4bdd0a4a08774914855480cb211e8782,
title = "Laparoscopic sleeve gastrectomy in morbidly obese patients with end-stage heart failure and left ventricular assist device: Medium-term results",
abstract = "Background Morbid obesity precludes patients with end-stage heart failure from becoming cardiac transplant candidates. This study evaluates the safety and efficacy of laparoscopic sleeve gastrectomy (LSG) as a means to transplant candidacy in such patients. Methods Morbidly obese patients with end-stage heart failure, who were ineligible for cardiac transplantation and underwent LSG between 2008 and 2013, were reviewed retrospectively. Demographic characteristics, perioperative details, percentage of excess weight loss ({\%}EWL), and status of transplant candidacy were analyzed. Results Six patients (3 men) with end-stage heart failure and morbid obesity underwent LSG. Three patients (50{\%}) had a left ventricular assist device (LVAD) in place at the time of surgery. Median age was 34 (31-66) years and mean preoperative body mass index (BMI) was 47.6±3.0 kg/m2. Median operative time was 90 (66-141) minutes, with a median length of stay of 7 (4-16) days. There were no perioperative deaths. One patient suffered a spontaneous flank hematoma. The same patient also had thrombosis of the LVAD pump at 3 weeks postoperatively, requiring an uneventful device exchange. At median follow-up of 22 (12-70) months, the mean {\%}EWL was 51.4±10.3{\%} with a decrease in BMI to 34.3±2.4 kg/m2 (P<.05). All patients had lost sufficient weight to become transplant eligible within 12 months of surgery. Two patients had undergone successful transplantation and another 2 were on the transplant list. Conclusion LSG appears to be a safe, technically feasible, and effective method for obtaining adequate weight loss in morbidly obese patients with end-stage heart failure and mechanical circulatory support, subsequently improving their access to cardiac transplantation. This is the largest case series to date of this high-risk group of patients undergoing LSG.",
author = "Chaudhry, {Umer I.} and Aliyah Kanji and {Sai Sudhakar}, Chittoor and Higgins, {Robert S.} and Needleman, {Bradley J.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1016/j.soard.2014.04.003",
language = "English (US)",
volume = "11",
pages = "88--93",
journal = "Surgery for Obesity and Related Diseases",
issn = "1550-7289",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Laparoscopic sleeve gastrectomy in morbidly obese patients with end-stage heart failure and left ventricular assist device

T2 - Medium-term results

AU - Chaudhry, Umer I.

AU - Kanji, Aliyah

AU - Sai Sudhakar, Chittoor

AU - Higgins, Robert S.

AU - Needleman, Bradley J.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Background Morbid obesity precludes patients with end-stage heart failure from becoming cardiac transplant candidates. This study evaluates the safety and efficacy of laparoscopic sleeve gastrectomy (LSG) as a means to transplant candidacy in such patients. Methods Morbidly obese patients with end-stage heart failure, who were ineligible for cardiac transplantation and underwent LSG between 2008 and 2013, were reviewed retrospectively. Demographic characteristics, perioperative details, percentage of excess weight loss (%EWL), and status of transplant candidacy were analyzed. Results Six patients (3 men) with end-stage heart failure and morbid obesity underwent LSG. Three patients (50%) had a left ventricular assist device (LVAD) in place at the time of surgery. Median age was 34 (31-66) years and mean preoperative body mass index (BMI) was 47.6±3.0 kg/m2. Median operative time was 90 (66-141) minutes, with a median length of stay of 7 (4-16) days. There were no perioperative deaths. One patient suffered a spontaneous flank hematoma. The same patient also had thrombosis of the LVAD pump at 3 weeks postoperatively, requiring an uneventful device exchange. At median follow-up of 22 (12-70) months, the mean %EWL was 51.4±10.3% with a decrease in BMI to 34.3±2.4 kg/m2 (P<.05). All patients had lost sufficient weight to become transplant eligible within 12 months of surgery. Two patients had undergone successful transplantation and another 2 were on the transplant list. Conclusion LSG appears to be a safe, technically feasible, and effective method for obtaining adequate weight loss in morbidly obese patients with end-stage heart failure and mechanical circulatory support, subsequently improving their access to cardiac transplantation. This is the largest case series to date of this high-risk group of patients undergoing LSG.

AB - Background Morbid obesity precludes patients with end-stage heart failure from becoming cardiac transplant candidates. This study evaluates the safety and efficacy of laparoscopic sleeve gastrectomy (LSG) as a means to transplant candidacy in such patients. Methods Morbidly obese patients with end-stage heart failure, who were ineligible for cardiac transplantation and underwent LSG between 2008 and 2013, were reviewed retrospectively. Demographic characteristics, perioperative details, percentage of excess weight loss (%EWL), and status of transplant candidacy were analyzed. Results Six patients (3 men) with end-stage heart failure and morbid obesity underwent LSG. Three patients (50%) had a left ventricular assist device (LVAD) in place at the time of surgery. Median age was 34 (31-66) years and mean preoperative body mass index (BMI) was 47.6±3.0 kg/m2. Median operative time was 90 (66-141) minutes, with a median length of stay of 7 (4-16) days. There were no perioperative deaths. One patient suffered a spontaneous flank hematoma. The same patient also had thrombosis of the LVAD pump at 3 weeks postoperatively, requiring an uneventful device exchange. At median follow-up of 22 (12-70) months, the mean %EWL was 51.4±10.3% with a decrease in BMI to 34.3±2.4 kg/m2 (P<.05). All patients had lost sufficient weight to become transplant eligible within 12 months of surgery. Two patients had undergone successful transplantation and another 2 were on the transplant list. Conclusion LSG appears to be a safe, technically feasible, and effective method for obtaining adequate weight loss in morbidly obese patients with end-stage heart failure and mechanical circulatory support, subsequently improving their access to cardiac transplantation. This is the largest case series to date of this high-risk group of patients undergoing LSG.

UR - http://www.scopus.com/inward/record.url?scp=84925193310&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925193310&partnerID=8YFLogxK

U2 - 10.1016/j.soard.2014.04.003

DO - 10.1016/j.soard.2014.04.003

M3 - Article

VL - 11

SP - 88

EP - 93

JO - Surgery for Obesity and Related Diseases

JF - Surgery for Obesity and Related Diseases

SN - 1550-7289

IS - 1

ER -